In contrast, DRAK2 low-expressing patients showed a significantly shorter OS than DRAK2 high-expressing patients (p = 0.003), suggesting that DRAK2 could be a new prognostic indicator in CLL (Figure 1C). Here, STK17B is linked to B-cell chronic lymphocytic leukemia.